{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T10:44:50Z","timestamp":1781347490382,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.taap.2019.114619","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T15:05:42Z","timestamp":1560179142000},"page":"114619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol"],"prefix":"10.1016","volume":"378","author":[{"given":"Ta-Chung","family":"Chao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueh-Ching","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Sou\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6046-8356","authenticated-orcid":false,"given":"Yune-Fang","family":"Ueng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2019.114619_bb0005","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2217\/pgs.15.30","article-title":"GenoChip CYP2D6 macroarray as a method to genotype for CYP2D6 variants: results of a validation study in a Caucasian population","volume":"16","author":"Bank, P.C","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.taap.2019.114619_bb0010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cca.2008.12.005","article-title":"Apolipoprotein E4 allele influences the response of plasma triglyceride levels to tamoxifen in breast cancer patients","volume":"401","author":"Chang","year":"2009","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.taap.2019.114619_bb0015","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ijo.2015.205","article-title":"Body mass index and breast cancer: analysis of a nation-wide population-based prospective cohort study on 1393985 Taiwanese women","volume":"40","author":"Chen","year":"2016","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.taap.2019.114619_bb0020","article-title":"Addressing adherence using genotype-specific PBPK modeling-impact of drug holidays on tamoxifen and endoxifen plasma levels","volume":"8","author":"Dickshen","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.taap.2019.114619_bb0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1210\/me.2007-0383","article-title":"27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator","volume":"22","author":"DuSell","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.taap.2019.114619_bb0030","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1200\/JCO.2017.76.3524","article-title":"Diabetes after hormone therapy in breast cancer survivors: a case-cohort study","volume":"36","author":"Hamood","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2019.114619_bb0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejca.2017.05.002","article-title":"Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: a propensity score-matched cohort study","volume":"82","author":"Hong","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.taap.2019.114619_bb0040","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1124\/jpet.110.178301","article-title":"P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration","volume":"337","author":"Iusuf","year":"2011","journal-title":"J. Pharmacol. Exp. Thera."},{"key":"10.1016\/j.taap.2019.114619_bb0045","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s10549-018-4876-x","article-title":"CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy","volume":"171","author":"Jansen","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.taap.2019.114619_bb0050","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00204-017-2147-y","article-title":"The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes","volume":"92","author":"Joh\u00e4nning","year":"2018","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.taap.2019.114619_bb0055","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/B:BREA.0000025406.31193.e8","article-title":"Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen","volume":"85","author":"Johnson","year":"2004","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.taap.2019.114619_bb0060","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cts.12542","article-title":"Cytochrome P450 genetic variation associated with tamoxifen biotransformation in American Indian and Alaska native people","volume":"11","author":"Khan","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.taap.2019.114619_bb0065","doi-asserted-by":"crossref","first-page":"59640","DOI":"10.18632\/oncotarget.10746","article-title":"High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer","volume":"7","author":"Kimbung","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.taap.2019.114619_bb0070","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2133\/dmpk.DMPK-11-RV-084","article-title":"Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters","volume":"27","author":"Kiyotani","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.taap.2019.114619_bb0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10549-011-1777-7","article-title":"Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients","volume":"131","author":"Kiyotani","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.taap.2019.114619_bb0080","unstructured":"Kleinbaum D., Kupper L., Nizam A., Rosenberg E., 2013. Chapter 10, Correlations: multiple, partial, and multiple partial. In: Applied Regression Analysis and Other Multivariable Methods, 5th edition, Cengage Learning, Boston, MA, USA, (ISBN-13: 978\u20131285051086)."},{"key":"10.1016\/j.taap.2019.114619_bb0085","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40262-017-0555-z","article-title":"Exploiting pharmacokinetic models of tamoxifen and endoxifen to identify factors causing subtherapeutic concentrations in breast cancer patients","volume":"57","author":"Klopp-Schulze","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.taap.2019.114619_bb0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10549-004-5449-8","article-title":"Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations","volume":"88","author":"Kusama","year":"2004","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.taap.2019.114619_bb0095","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/ijc.31291","article-title":"The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population","volume":"143","author":"Lan","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.taap.2019.114619_bb0100","first-page":"3585","article-title":"Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population","volume":"8","author":"Lei","year":"2016","journal-title":"Amer. J. Transl. Res."},{"key":"10.1016\/j.taap.2019.114619_bb0105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1185\/03007995.2013.858619","article-title":"Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia","volume":"30","author":"Li","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.taap.2019.114619_bb0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000077360","article-title":"Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in chinese schizophrenic patients","volume":"49","author":"Liou","year":"2004","journal-title":"Neuropsychobiol"},{"key":"10.1016\/j.taap.2019.114619_bb0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1023\/A:1023348021773","article-title":"Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction","volume":"79","author":"Liu","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.taap.2019.114619_bb0120","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/clpt.2011.32","article-title":"Tamoxifen metabolite concentrations, CYP2D6 genotype and breast cancer outcomes","volume":"89","author":"Madlensky","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2019.114619_bb0125","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1124\/dmd.108.026096","article-title":"Two novel CYP2D6*10 haplotypes as a possible causes of a poor metabolic phenotype in Japanese","volume":"37","author":"Matsunaga","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2019.114619_bb0130","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0006-291X(02)00328-5","article-title":"CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability","volume":"293","author":"Nakamura","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2019.114619_bb0135","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jfma.2015.05.006","article-title":"Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients","volume":"115","author":"Pan","year":"2016","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.taap.2019.114619_bb0140","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1124\/dmd.108.023242","article-title":"Functional characterization of 17 CYP2D6 allelic (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57)","volume":"36","author":"Sakuyama","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2019.114619_bb0145","doi-asserted-by":"crossref","DOI":"10.1515\/cclm-2017-0409","article-title":"Selective changes in cholesterol metabolite levels in plasma of breast cancer patients after tumor removal","volume":"56","author":"Sou\u010dek","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.taap.2019.114619_bb0150","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1002\/cncr.27527","article-title":"Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer","volume":"118","author":"Sparano","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.taap.2019.114619_bb0155","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1124\/dmd.110.036160","article-title":"Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1)","volume":"39","author":"Teft","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2019.114619_bb0160","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/1534735416684014","article-title":"The effect of Undaria pinnatifida Fucoidan on the pharmacokinetics of letrozole and tamoxifen in patients with breast cancer","volume":"17","author":"Tocaciu","year":"2018","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.taap.2019.114619_bb0165","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0009-9236(96)90133-2","article-title":"Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes","volume":"60","author":"Tseng","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2019.114619_bb0170","doi-asserted-by":"crossref","first-page":"66033","DOI":"10.18632\/oncotarget.19789","article-title":"7-Ketocholesterol and 27-hydroxycholesterol decreased doxorubicin sensitivity in breast cancer cells: estrogenic activity and mTOR pathway","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.taap.2019.114619_bb0175","series-title":"Breast Cancer","first-page":"111","article-title":"CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study","volume":"9","author":"Wickramage","year":"2017"},{"key":"10.1016\/j.taap.2019.114619_bb0180","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/annonc\/mdn155","article-title":"Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment","volume":"19","author":"Xu","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.taap.2019.114619_bb0185","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.breast.2016.04.017","article-title":"Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients","volume":"28","author":"Yang","year":"2016","journal-title":"Breast"}],"updated-by":[{"DOI":"10.1016\/j.taap.2019.114701","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000}}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X19302212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X19302212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T13:36:23Z","timestamp":1617716183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X19302212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":37,"alternative-id":["S0041008X19302212"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2019.114619","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.taap.2019.114701","asserted-by":"object"}]},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2019.114619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114619"}}